Hikari Power LTD Akari Therapeutics PLC Transaction History

Hikari Power LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 13, 2022	BUY	$1.09 - $1.53 $44,696 - $62,739	41,006 Added 45.66%	130,821 $157,000
Q3 2020 Oct 08, 2020	SELL	$1.58 - $2.37 $2.23 Million - $3.34 Million	-1,410,281 Reduced 94.01%	89,815 $156,000
Q3 2019 Oct 31, 2019	BUY	$1.69 - $2.92 $169,000 - $292,000	100,000 Added 7.14%	1,500,096 $2.57 Million
Q2 2019 Aug 08, 2019	SELL	$1.89 - $4.01 $56,700 - $120,300	-30,000 Reduced 2.1%	1,400,096 $2.83 Million
Q1 2019 Apr 26, 2019	BUY	$1.66 - $5.9 $382,462 - $1.36 Million	230,399 Added 19.2%	1,430,096 $5.12 Million
Q4 2018 Jan 29, 2019	BUY	$1.57 - $2.49 $313,524 - $497,245	199,697 Added 19.97%	1,199,697 $1.88 Million
Q3 2018 Oct 31, 2018	BUY	$1.82 - $2.56 $284,194 - $399,746	156,151 Added 18.5%	1,000,000 $2.56 Million
Q2 2018 Aug 02, 2018	BUY	$1.77 - $2.28 $367,285 - $473,113	207,506 Added 32.61%	843,849 $1.65 Million
Q1 2018 May 14, 2018	BUY	$1.77 - $4.39 $858,465 - $2.13 Million	485,009 Added 320.49%	636,343 $1.16 Million
Q3 2017 Nov 08, 2017	BUY	$3.42 - $8.74 $312,321 - $798,154	91,322 Added 152.17%	151,334 $929,000
Q2 2017 Aug 09, 2017	BUY	N/A	60,012	60,012 $277,000

Ticker AKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,349,200
Market Cap $123M
Description
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-...

Get notified when there are updates to the investment portfolio of Hikari Power LTD, based on Form 13F filings with the SEC.

Stay updated on Hikari Power LTD with notifications on news.